CryoCath
This article was originally published in The Gray Sheet
Executive Summary
Company reps meet with FDA June 4 to discuss a trial design for the Artic Circler atrial fibrillation ablation catheter; firm hopes to begin an IDE trial later this year. The meeting came two days after FDA's Circulatory System Devices Panel unanimously voted against recommending approval of Cardima's Revelation Tx AF ablation catheter, largely due to difficulties in obtaining AF burden data from patients (1"The Gray Sheet" June 2, 2003, p. 3)...
You may also be interested in...
Cardima’s Revelation: AF Self-Monitoring, Hazy Endpoints Hamper Review
The ability of self-reporting to accurately track reduction in atrial fibrillation burden is cast into doubt by FDA panel experience with Cardima's Revelation ablation system data submission
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.